Fig. 3: Survival of patients according to different CAR T-cell therapies. | Blood Cancer Journal

Fig. 3: Survival of patients according to different CAR T-cell therapies.

From: Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

Fig. 3: Survival of patients according to different CAR T-cell therapies.The alternative text for this image may have been generated using AI.

A Overall survival B leukemia-free survival and C cumulative incidence of relapse of patients in the single CD19 group, tandem CD19/CD22 group and sequential CD19/CD22 group. D Overall survival E leukemia-free survival and F cumulative incidence of relapse of patients who underwent allo-HSCT after CAR T-cell therapy among the three groups. G Overall survival H leukemia-free survival and I cumulative incidence of relapse of patients without allo-HSCT after CAR T-cell therapy among the three groups.

Back to article page